Cargando…

Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive disorder in which the most noticeable symptoms are cognitive impairment and memory loss. However, the precise mechanism by which those symptoms develop remains unknown. Of note, neuronal loss occurs at sites where synaptic dysfunction is observed earlier, su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerrero-Muñoz, Marcos J., Gerson, Julia, Castillo-Carranza, Diana L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667007/ https://www.ncbi.nlm.nih.gov/pubmed/26696824 http://dx.doi.org/10.3389/fncel.2015.00464

Ejemplares similares

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
por: Shafiei, Scott S., et al.
Publicado: (2017)

α-Synuclein Oligomers Induce a Unique Toxic Tau Strain
por: Castillo-Carranza, Diana L., et al.
Publicado: (2018)

The prion-like transmission of tau oligomers via exosomes
por: Jackson, Noel A., et al.
Publicado: (2022)

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau
por: Lasagna-Reeves, Cristian A., et al.
Publicado: (2012)

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
por: Gerson, Julia E., et al.
Publicado: (2018)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
por: Castillo-Carranza, Diana L, et al.
Publicado: (2017)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases
por: Nilson, Ashley N., et al.
Publicado: (2016)

Tau Oligomers as Potential Targets for Alzheimer’s Diagnosis and Novel Drugs
por: Guzmán-Martinez, Leonardo, et al.
Publicado: (2013)

Characteristics of Tau Oligomers
por: Ren, Yan, et al.
Publicado: (2013)

Hyperphosphorylation-Induced Tau Oligomers
por: Iqbal, Khalid, et al.
Publicado: (2013)

Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease
por: Marcatti, Michela, et al.
Publicado: (2022)

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2014)

A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2015)

Single-synapse analyses of Alzheimer’s disease implicate pathologic tau, DJ1, CD47, and ApoE
por: Phongpreecha, Thanaphong, et al.
Publicado: (2021)

Targeting the Synapse in Alzheimer’s Disease
por: Jackson, Johanna, et al.
Publicado: (2019)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease
por: Zhang, Yuan, et al.
Publicado: (2019)

Detrimental effects of soluble α-synuclein oligomers at excitatory glutamatergic synapses
por: Ferrari, Elena, et al.
Publicado: (2023)

The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer’s Disease (AD)
por: Mroczko, Barbara, et al.
Publicado: (2019)

Meet the players: local translation at the synapse
por: Fernandez-Moya, Sandra M., et al.
Publicado: (2014)

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2011)

Synapses, Microglia, and Lipids in Alzheimer’s Disease
por: Paasila, Patrick J., et al.
Publicado: (2022)

Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives
por: Lo Cascio, Filippa, et al.
Publicado: (2019)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer’s Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers
por: Singh, Ayush, et al.
Publicado: (2020)

Chaperones as Suppressors of Protein Misfolded Oligomer Toxicity
por: Mannini, Benedetta, et al.
Publicado: (2017)

“Tau Oligomers,” What We Know and What We Don’t Know
por: Sahara, Naruhiko, et al.
Publicado: (2014)

PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s Disease
por: Luna-Viramontes, Nabil Itzi, et al.
Publicado: (2020)

Formation and Propagation of Tau Oligomeric Seeds
por: Gerson, Julia E., et al.
Publicado: (2013)

Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease
por: Rudajev, Vladimir, et al.
Publicado: (2022)

TIA1 regulates the generation and response to toxic tau oligomers
por: Jiang, Lulu, et al.
Publicado: (2018)

Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer’s disease
por: Puangmalai, Nicha, et al.
Publicado: (2022)

The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
por: Viola, Kirsten L., et al.
Publicado: (2022)

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015)

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
por: Hector, Audrey, et al.
Publicado: (2021)

Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain
por: DeVos, Sarah L., et al.
Publicado: (2018)

Synapses, Synaptic Activity and Intraneuronal Aβ in Alzheimer's Disease
por: Tampellini, Davide, et al.
Publicado: (2010)

Commentary: APP as a Mediator of the Synapse Pathology in Alzheimer's Disease
por: Schreurs, An, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u4boij2rqbkka6ajnkk17k6jdr